Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795769 · ClinicalTrials.gov registry record · Phase 2
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00795769 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 49 participants.
The verdict
NCT00795769, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients undergoing stem cell transplant.
Interventions
- OTHER survey administration
- PROCEDURE management of therapy complications
- DRUG ondansetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2008-08-08 |
| Est. Completion | 2009-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00795769
The ClinicalTrials.gov registry entry for NCT00795769 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which survey administration is the first listed.
NCT00795769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00795769 about?
NCT00795769 is a clinical study titled "Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant". RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients undergoing stem cell transplant.
What is the current status of trial NCT00795769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2008-08-08. Estimated completion is 2009-06-10.
What interventions are being tested in trial NCT00795769?
The interventions under investigation include: survey administration (OTHER), management of therapy complications (PROCEDURE), ondansetron (DRUG).
Who is sponsoring clinical trial NCT00795769?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.